Seth Ashok, Kumar Vijay, Singh Vivudh Pratap, Kumar Dhananjay, Varma Puneet, Rastogi Vishal
Interventional Cardiology and Structural Therapies, Fortis Escorts Heart Institute New Delhi, India.
Interv Cardiol. 2023 Apr 10;18:e12. doi: 10.15420/icr.2020.32. eCollection 2023.
Transcatheter aortic valve implantation (TAVI) performed using femoral arterial access is now a guideline recommended treatment for severe calcific aortic stenosis (AS) in elderly patients. Technological advancements and procedural refinements have focused on making TAVI simpler, safer, more effective and durable. Myval (Meril Lifesciences) is a new generation balloon-expandable transcatheter heart valve (THV) developed in India that possesses novel features to improve deliverability and aid precise deployment. Following the first-in-human study, Myval was approved in India for commercial implantation in October 2018 and was subsequently given a CE mark in April 2019. This article reviews the science, technology and up-to-date clinical evidence for the Myval THV.
经股动脉入路进行的经导管主动脉瓣植入术（TAVI）目前是老年患者严重钙化性主动脉瓣狭窄（AS）的指南推荐治疗方法。技术进步和操作改进一直致力于使TAVI更简单、更安全、更有效且更持久。Myval（梅里尔生命科学公司）是一款在印度研发的新一代球囊扩张式经导管心脏瓣膜（THV），具有改善输送性和辅助精确植入的新特性。在首例人体研究之后，Myval于2018年10月在印度获批用于商业植入，并于2019年4月随后获得CE标志。本文回顾了Myval THV的科学、技术及最新临床证据。
Zotero 插件